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Tissue Typing Laboratory, Regional Blood Transfusion Service,
Material and methods
Three hundred and forty-eight first cadaver-donor transplants were performed from 30 October 1969 to 10 May 1980 and 81 first liverelated donor transplants from 30 January 1967 to 26 February 1980. All cases were assessed for graft survival in July 1980.
Tissue typing and crossmatching-Tissue typing for HLA-A and HLA-B antigens was carried out as described. ' HLA-DR antigens (DR1-DRw8) were determined prospectively on donor-recipient pairs from May 1978. The antisera used for DR typing were assessed against cells typed for HLA-DR antigens by Seventh and Eighth Histocompatibility Workshop antisera. Pretransplant lymphocytotoxic cross-matching was performed as described3 using both fresh recipient serum and all previous samples stored frozen at -20°C. The first 232 cross-matches were performed using whole lymphocyte suspensions prepared from peripheral blood, lymph node, or spleen. In the subsequent 116 cases separated T and B lymphocytes from the cadaver material were used, and only lymphocytotoxic antibody in the recipient's serum reactive against the T lymphocytes was regarded as a contraindication to transplantation. Cross-match tests were performed at 37°C for the first 102 cases but at both 20°C and 37°C for all subsequent cases.
Pretransplant transfusion history-Transfusion histories were compiled as described.4
Clinical management and immunosuppression Our methods of clinical care have been described '2 HLA-DR matching-Sixty-four consecutive first cadaver-donor transplants were typed for HLA-DR antigens. Two cases were excluded because no HLA-DR typing results could be obtained for the donor owing to the poor condition of the cadaver material. Eleven transplants failed for reasons unconnected with rejection. Of the 51 recipients available for analysis, 49 had been transfused. Two recipients matched their donors for two DR antigens and in both cases the grafts were surviving at the time of assessment. Nevertheless, both patients were transfused recipients and matched for HLA-B antigens, who in our study represented a privileged group. Twentytwo recipients were matched for one DR antigen and their 12-month graft survival was 79%, while 25 recipients had no measurable DR antigens in common and had a graft survival of 80%. Thus, in this group of transfused graft recipients matching for one DR antigen appeared to offer no advantage.
HLA-B and DR matching-In this series of 62 HLA-DR typed transplants the number of cases matched for two, one, and no DR antigens within the group matched for HLA-B antigens were 2, 19, and 18 respectively and in the non-HLA-B matched group, 0, 11, and 12 respectively. The advantages of HLA-B antigen matching were not, therefore, due to matching for DR by linkage disequilibrium.
CHANGE OF POLICY IN NEWCASTLE
Early in 1978 we decided to perform transplants only on patients who had been transfused and to attempt to increase the proportion of HLA-B antigen matches. In addition, the other minor changes in initial immunosuppressive and antibiotic treatment were introduced. Sixty-four first transplants have been performed under this policy.
The proportion of transfused recipients rose from 63% to 95% and of HLA-B antigen matches from 3400 to 62%.
Since the implementation of these changes the actuarial graft survival at 24 months has improved significantly from 63% to 78% (p=0 025); furthermore, the graft survival was 82% in 32 HLA-B matched cases compared with 74% in 19 unmatched recipients (p---0 1). The HLA-B matched and unmatched patients did not differ in transfusion history, age or sex distribution, or duration of dialysis before transplantation.
Discussion
The results of first cadaver-donor transplants in Newcastle upon Tyne show that matching for two HLA-B locus antigens continues to give significantly improved graft survival in previously transfused recipients. Indeed, the graft survival in this group of recipients is better than that achieved in the one haplotype matches from either parent or sibling live-donor transplants.
The beneficial effect of matching for two HLA-B locus antigens was first reported by Oliver et a18 and supported by earlier reports from the Newcastle centre.2 Brynger and Gelin9 have recently reported graft loss to be significantly associated with HLA-B antigen incompatibility.
When we began DR typing it had been reported that DR matching for one or two antigens gave a graded benefit.0 -12 A more recent study, however, shows that DR matching confers benefit only if there are no mismatches.'3 Only two of our donorrecipient pairs were matched for two DR antigens; our analysis consisted of comparing 22 patients matched for one DR antigen with 25 who had no measurable DR antigens in common.
Furthermore, although Ting and Morris13 found benefit from DR matching in transfused patients, this was small. Most of our patients in whom DR typing was performed had been transfused (49 out of 51 recipients analysed). We have no data on the effect of DR matching in non-transfused recipients. Until further evidence on the value of DR matching becomes available we intend to continue with our present policy of pretransplant transfusion and of matching for HLA-B locus antigens.
We have been encouraged that both pretransplant blood transfusion and HLA-B antigen matching have, over two years, .
. s been accompanied by a significantly reduced rate of total rejection in our patients. We cannot, of course, be certain that the introduction of the initial higher dose of azathioprine and of the two early boluses of methylprednisolone did not also contribute to the improved results. Nevertheless, the improvement was in keeping with our previous finding of benefit from transfusion and HLA-B matching. The object of a kidney-sharing scheme must be to ensure that the recipients of the organs receive the maximum benefit and that rejection rates are kept as low as possible by suitable tissue matching. Furthermore, the shortage of donor organs and the cost of matching, sharing, and transporting kidneys demands that the best use should be made of available resources.
In our patients matching for B locus antigens was more important than that for A locus antigens and (in a small sample) one DR locus antigen. The accuracy and completeness of the data are likely to be greater in a single-centre analysis than in multicentre national or international studies. We invite other centres to examine their data to see if they agree or disagree with this conclusion. If there are no conflicting results we urge the UK Transplant Service to change over to B locus matching as its main criterion for distributing kidneys pending further information on the value of full DR matching.
Introduction
Trimethoprim is now registered in several countries for prophylaxis and treatment of urinary tract infections: in Finland this happened as early as 1973.1 In 1980 we found that 316% of bacterial strains isolated from hospital patients (Pseudomonas excluded) were resistant to trimethoprim.2 The specimens were received from Turku City Hospital and the health centre wards in Turku. We have now compared the prevalence of resistance in Turku City Hospital with that in two university hospitals. We also studied bacterial resistance to sulphamethoxazoletrimethoprim, sulphamethoxazole, ampicillin, and nitrofurantoin. 
